• Samuel Romero, Juan Montoro, Marta Guinot, Luis Almenar, Rafael Andreu, Aitana Balaguer, Isabel Beneyto, Jordi Espí, José Gómez-Codina, Gloria Iacoboni, Isidro Jarque, Rafael López-Andújar, Empar Mayordomo-Aranda, Joaquín Montalar, Amparo Pastor, Miguel Pastor, José L Piñana, Nohelia Rojas-Ferrer, Ignacio Sánchez-Lázaro, Jesús Sandoval, Guillermo Sanz, Miguel Á Sanz, Amparo Solé, and Jaime Sanz.
• a Hematology Department , Hospital Universitario y Politécnico La Fe , Valencia , Spain.
• Leuk. Lymphoma. 2019 Jan 1; 60 (1): 142-150.

AbstractPost-transplant lymphoproliferative disorders (PTLD) are a rare complication after both solid organ (SOT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this single center retrospective study, we compared clinical, biological, and histological features, and outcomes of PTLD after both types of transplant. We identified 82 PTLD (61 after SOT and 21 after allo-HSCT). The presence of B symptoms, Waldeyer ring, spleen, central nervous system, and liver involvement, and advanced Ann-Arbor stage were more frequent in allo-HSCT recipients. PTLD had an earlier onset in allo-HSCT than in SOT cohort (4 vs. 64 months, p < .0001). PTLD was EBV-positive in 100% of allo-HSCT, in contrast to 47% of SOT (p = .0002). Four years after PTLD diagnosis, median overall survival was 32% (95% CI, 22-48) and 10% (95% CI, 2-49) in SOT and allo-HSCT recipients, respectively (p = .002). In conclusion, the clinical presentation and the outcome of PTLD varies greatly depending on the type of transplant.

43 keywords...

hide…